| Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized, placebo-controlled study. | |
| | |
MedLine Citation:
|
PMID: 20691026 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Median survival times (STs) for doxorubicin-treated canine lymphoma range from 5.7 to 9 months. Because dogs treated with multi-agent protocols have longer STs, we sought to evaluate whether adding cyclophosphamide would improve outcome in canine lymphoma patients while maintaining an acceptable level of toxicity. Thirty-two dogs with stage III-V multicentric lymphoma were treated with doxorubicin every 3 weeks for five total cycles and prednisone at a tapering dose for the first 4 weeks. Dogs were randomized to receive either cyclophosphamide or placebo concurrently. Seventeen dogs received doxorubicin and placebo, while 15 dogs received doxorubicin and cyclophosphamide. Response, toxicity, progression-free interval (PFI) and ST were evaluated. The combination of doxorubicin and cyclophosphamide was well tolerated, causing no increase in adverse events over doxorubicin alone. Despite a numeric improvement in outcome in cyclophosphamide treated dogs, the addition of cyclophosphamide did not result in statistically improved response rate, PFI or ST. |
| | |
Authors:
|
J C Lori; T J Stein; D H Thamm |
Related Documents
:
|
12634726 - Osteosarcoma after allogeneic bone marrow transplantation. a report of four cases from ... 1911456 - Zürich experience with preoperative, high dose methotrexate-containing chemotherapy in... 2386906 - Pediatric osteosarcoma. successful retreatment of relapsed primary tumor and soft tissu... 6571796 - Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichlorop... 12634726 - Osteosarcoma after allogeneic bone marrow transplantation. a report of four cases from ... 21475636 - Mature results of a prospective randomized trial comparing 5-flourouracil with leucovor... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Veterinary and comparative oncology Volume: 8 ISSN: 1476-5829 ISO Abbreviation: Vet Comp Oncol Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-09 Completed Date: 2010-12-13 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 101185242 Medline TA: Vet Comp Oncol Country: England |
Other Details:
|
Languages: eng Pagination: 188-95 Citation Subset: IM |
Affiliation:
|
Animal Cancer Center, Colorado State University College of Veterinary Medicine, Fort Collins, CO 80523-1620, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibiotics, Antineoplastic / administration & dosage, adverse effects Antineoplastic Agents, Alkylating / administration & dosage, adverse effects, therapeutic use* Antineoplastic Agents, Hormonal / administration & dosage, adverse effects Antineoplastic Combined Chemotherapy Protocols / adverse effects, therapeutic use* Cyclophosphamide / administration & dosage, adverse effects, therapeutic use* Disease-Free Survival Dog Diseases / drug therapy* Dogs Doxorubicin / administration & dosage*, adverse effects Female Lymphoma / drug therapy, veterinary* Male Neoplasm Staging Placebos Prednisone / administration & dosage, adverse effects Prognosis Schools, Veterinary Survival Analysis Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
1UL1RR025011/RR/NCRR NIH HHS; UL1 RR025011-01/RR/NCRR NIH HHS; UL1 RR025011-02/RR/NCRR NIH HHS; UL1 RR025011-03/RR/NCRR NIH HHS; UL1 RR025011-04/RR/NCRR NIH HHS; UL1 RR025011-05/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Antineoplastic Agents, Alkylating; 0/Antineoplastic Agents, Hormonal; 0/Placebos; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 53-03-2/Prednisone |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: PET/CT today and tomorrow in veterinary cancer diagnosis and monitoring: fundamentals, early results...
Next Document: Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy pr...